Current Perspectives on Circulating Tumor DNA, Precision Medicine, and Personalized Clinical Management of Cancer.

Autor:	Oliveira KCS; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Brazil., Ramos IB; Programa de Residência Multiprofissional em Saúde, Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, Brazil., Silva JMC; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Brazil., Barra WF; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Brazil., Riggins GJ; Brain Cancer Biology and Therapy Research Laboratory, Johns Hopkins Medicine, Baltimore, Maryland., Palande V; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel., Pinho CT; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Brazil., Frenkel-Morgenstern M; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel., Santos SEB; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Brazil., Assumpcao PP; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Brazil., Burbano RR; Laboratório de Biologia Molecular, Hospital Ophir Loyola, Belém, Brazil., Calcagno DQ; Núcleo de Pesquisas em Oncologia, Universidade Federal do Pará, Belém, Brazil. danicalcagno@gmail.com.
Jazyk:	angličtina
Zdroj:	Molecular cancer research : MCR [Mol Cancer Res] 2020 Apr; Vol. 18 (4), pp. 517-528. Date of Electronic Publication: 2020 Jan 29.
DOI:	10.1158/1541-7786.MCR-19-0768
Abstrakt:	Circulating tumor DNA (ctDNA) has recently emerged as a minimally invasive "liquid biopsy" tool in precision medicine. ctDNA-genomic DNA fragments that are released into the bloodstream after the active secretion of microvesicles or tumor cell lysis reflects tumor evolution and the genomic alterations present in primary and/or metastatic tumors. Notably, ctDNA analysis might allow the stratification of patients, the monitoring of the therapeutic response, and the establishment of an opportunity for early intervention independent of detection by imaging modalities or clinical symptoms. As oncology moves towards precision medicine, the information in ctDNA provides a means for the individual management of the patient based on their tumor's genetic profile. This review presents current evidence on the potential role for ctDNA in helping to guide individualized clinical treatment decisions for patients with melanoma, castration-resistant prostate cancer, breast cancer, metastatic colorectal cancer, and non-small cell lung cancer. (©2020 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu